Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain.

ABSTRACT: We previously developed LJ-4378, a dual ligand for A_2A and A₃ adenosine receptors, as a potential anti-obesity agent. In this study, we compared the anti-obesity effects of LJ-4378 with those of tirzepatide (TZP), a dual agonist of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, and one of the most potent FDA-approved obesity therapeutics. Using a mouse model of diet-induced obesity, we assessed the effects of LJ-4378 and TZP on body weight loss, metabolic parameters, and post-treatment weight rebound. Mice fed a high-fat diet (HFD) for 10 weeks were treated with vehicle, LJ-4378, or TZP for 14 days. Both LJ-4378 and TZP significantly reduced body weight, adipose tissue mass, and abdominal fat volume; improved glucose tolerance; red

SUBMITTER: Kim H 

PROVIDER: S-EPMC12680861 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature